The estimated Net Worth of Corinne H Nevinny is at least $2.96 million dollars as of 13 May 2021. Ms. Nevinny owns over 933 units of Insulet stock worth over $762,896 and over the last 20 years she sold PODD stock worth over $1,712,377. In addition, she makes $482,843 as Independent Director at Insulet.
Corinne has made over 12 trades of the Insulet stock since 2013, according to the Form 4 filled with the SEC. Most recently she sold 933 units of PODD stock worth $215,915 on 13 May 2021.
The largest trade she's ever made was exercising 15,000 units of Insulet stock on 2 May 2018 worth over $105,750. On average, Corinne trades about 1,903 units every 53 days since 2004. As of 13 May 2021 she still owns at least 3,350 units of Insulet stock.
You can see the complete history of Ms. Nevinny stock trades at the bottom of the page.
Corinne H. Nevinny serves as Independent Director of the Company. Ms. Nevinny has served on our Board of Directors since January 2019. Since 2010, she has served as General Partner at LMNVC, LLC, a seed venture fund making early-round investments in start-up companies that have products or provide services to improve quality of life, including health and wellness oriented businesses. From 2003 to 2010, she served in various roles at Edwards Lifesciences Corporation, a global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring, including General Manager - Cardiac Surgery Systems, President of Global Operations, and Chief Financial Officer and Treasurer. During this time, Ms. Nevinny was responsible for global manufacturing, quality and supply chain operations, as well as oversight of core operating units including finance, IT, internal audit and risk management. Prior to joining Edwards Lifesciences Corporation, Ms. Nevinny held various finance and investment banking positions. Ms. Nevinny is a member of the Board of Trustees and Executive Committee of the United States Olympic and Paralympic Foundation and serves on the Board of Directors of Restorsea LLC. She previously served on the Board of Directors of privately-held nVision Medical Corp., a company focused on developing medical devices in the women’s health innovation space, as well as on the Boards of Directors of various public companies, including Edwards Life Sciences Corporation, Avanir Pharmaceuticals, Inc., Neurocrine Biosciences, Inc., Onyx Pharmaceuticals, Inc., and SangStat Medical Corp. Ms. Nevinny chaired the Audit Committees of Avanir Pharmaceuticals, Inc., Neurocrine Biosciences, Inc. and Onyx Pharmaceuticals, Inc. Ms. Nevinny brings considerable public board experience and a breadth of first-hand experience managing complex global finance, logistics, regulatory and manufacturing operations, which are directly relevant to our business.
As the Independent Director of Insulet, the total compensation of Corinne Nevinny at Insulet is $482,843. There are 11 executives at Insulet getting paid more, with Shacey Petrovic having the highest compensation of $5,883,980.
Corinne Nevinny is 60, she's been the Independent Director of Insulet since 2019. There are 5 older and 15 younger executives at Insulet. The oldest executive at Insulet Corporation is John Fallon, 72, who is the Independent Director.
Corinne's mailing address filed with the SEC is C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON, MA, 01720.
Over the last 18 years, insiders at Insulet have traded over $64,849,299 worth of Insulet stock and bought 175,262 units worth $7,280,516 . The most active insiders traders include Jonathan Silverstein, Elizabeth H Weatherman et Samuel D Colella. On average, Insulet executives and independent directors trade stock every 19 days with the average trade being worth of $2,473,148. The most recent stock trade was executed by Timothy J Scannell on 10 September 2024, trading 5,000 units of PODD stock currently worth $1,129,200.
insulet corporation is an innovative medical device company based in billerica, massachusetts. it was founded in 2000 with the mission of improving the lives of people with diabetes. specifically, through its revolutionary omnipod insulin management system, insulet seeks to expand the use of insulin pump therapy. studies have demonstrated the advantages of insulin pump therapy over multiple daily insulin injections (mdi); these advantages include better glycemic control, fewer hypoglycemic events, reduced glycemic variability1 and improved quality of life2. despite these benefits, most people still choose mdi therapy largely due to the complexity, cost and inconvenience of conventional pump technology. the omnipod is a discreet and easy-to-use system that eliminates many of the issues associated with conventional pumps. improvements include omnipod's lack of tubing; automated, virtually pain-free insertion; and two straightforward parts that communicate wirelessly. by breaking down
Insulet executives and other stock owners filed with the SEC include: